Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation

Area of Science:

• Immunology
• Gastroenterology
• Molecular Biology

Background:

• Chronic inflammatory bowel disease (IBD), especially Crohn's disease, involves an imbalance of T helper cell type 1 (Th1) and type 2 (Th2) responses.
• Interleukin-18 (IL-18), a key factor in Th1 polarization, acts synergistically with IL-12 and is implicated in IBD pathogenesis.
• Increased IL-18 expression is observed in Crohn's disease lesions, and its neutralization ameliorates experimental colitis.

Purpose of the Study:

• To investigate the role of IL-18 and its activating enzyme, ICE, in the pathogenesis of intestinal inflammation.
• To evaluate the therapeutic potential of inhibiting ICE in models of colitis.

Main Methods:

• Analysis of IL-18 expression in Crohn's disease patients.
• Administration of IL-18 neutralizing antibodies in experimental colitis models.
• Assessment of ICE activation in infectious colitis models.
• Evaluation of ICE knockout mice and ICE inhibitor (pralnacasan) treatment in experimental mucosal inflammation.

Main Results:

• IL-18 expression is elevated in inflamed tissues of Crohn's disease patients.
• Neutralization of IL-18 significantly reduces the severity of experimental colitis.
• ICE activation is crucial for intestinal inflammation in various colitis models.
• ICE knockout mice and pralnacasan treatment demonstrate protection against experimental mucosal inflammation.

Conclusions:

• IL-18 and ICE play significant roles in the pathogenesis of chronic intestinal inflammation and IBD.
• Inhibition of ICE presents a promising therapeutic strategy for inflammatory bowel disease.
• Further investigation of ICE inhibition in animal models is warranted.